More Production, More Revenue: Pharmaceutical Industry Makes Significant Gains - German pharma cuts US reliance as tariffs loom and exports shift

Germany's pharmaceutical industry has faced shifting trade pressures since the US announced planned tariffs in 2023. While the sector remains a key export driver, its reliance on the American market has dropped. Companies have adjusted by diversifying supply chains and expanding sales in Asia and the EU.

The US was once Germany's largest pharmaceutical export market, accounting for a quarter of all overseas sales. But its share fell from 12% of total exports in 2022 to just 9% in 2025. In 2024 alone, shipments to the US declined by 15% as tariffs loomed and firms redirected goods elsewhere.

At the start of 2025, many companies rushed orders to avoid potential USPS tariffs, creating a temporary boost. Despite this, domestic demand weakened in recent months. Yet the sector still grew, with production up 4.5% and revenue rising by 5.5% in 2025.

The industry's resilience comes from its heavy export focus—over 60% of revenue comes from abroad. However, competition from Asian producers has intensified, adding pressure. While USPS tariffs have not yet been imposed, uncertainty remains, leaving firms cautious about future trade with the US.

Germany's pharmaceutical sector has adapted by cutting dependence on the US and strengthening other markets. Growth in production and revenue shows its ability to weather trade disruptions. But with tariffs still a possibility, the industry must stay prepared for further challenges ahead.